UnknownNot applicableNCT04517019
Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy
Studying Sarcoma of cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Tuebingen
- Principal Investigator
- Cihan Gani, MD, PDUniversity Hospital Tübingen
- Intervention
- Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C(device)
- Enrollment
- 201 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (1)
- University Hospital Tübingen, Tübingen, Baden-Wurttemberg, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04517019 on ClinicalTrials.govOther trials for Sarcoma of cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07071727Short Course of Radiotherapy Prior to Surgery of Soft Tissue SarcomasThe Netherlands Cancer Institute
- RECRUITINGPHASE2NCT07192068Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.UNICANCER
- RECRUITINGPHASE1NCT06771219SLV-154 Treatment of Metastatic Solid TumorsSolve Therapeutics
- RECRUITINGNCT06904365Ovarian-Sparing Adaptive Radiotherapy in Young Adult WomenWashington University School of Medicine
- RECRUITINGPHASE2NCT06580002Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialUniversity of California, Irvine
- RECRUITINGNANCT06103669Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)University of California, Davis
- RECRUITINGNCT05366881cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseAdela, Inc
- RECRUITINGPHASE1, PHASE2NCT05187338Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsSecond Affiliated Hospital of Guangzhou Medical University